CLINICAL TRIALS PROFILE FOR KEFZOL
✉ Email this page to a colleague
All Clinical Trials for KEFZOL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00550290 ↗ | Prophylactic Antibiotics for Prevention of Wound Complications Following Vulvectomy | Completed | Aultman Health Foundation | Phase 4 | 2007-10-01 | This randomized prospective study will specifically investigate the efficacy of a 24 hour post-operative course of broad-spectrum prophylactic antibiotics - namely Cefazolin - in preventing wound infection and wound breakdown following vulvectomy. |
| NCT01295606 ↗ | Cefazolin Pharmacokinetics: Elimination Clearance in Neonates | Completed | Universitaire Ziekenhuizen Leuven | Phase 4 | 2011-02-01 | To document cefazolin disposition (concentration/time profile, protein binding, metabolism, renal elimination characteristics) and its covariates in neonates following intravenous administration of the drug at induction of anesthesia, prior to an invasive procedure To evaluate if optimalisation of cefazolin dose regimen during neonatal life is needed |
| NCT01991834 ↗ | Antibiotic Prophylaxis in Gynecologic Laparoscopy | Completed | Universidade do Vale do Sapucai | N/A | 2013-09-01 | Laparoscopy is a surgical procedure indicated for most gynecological pathologies and presents numerous advantages over laparotomy, among them lower rates of surgical site infection and less comorbidity feverish. Despite this, the use of antibiotic prophylaxis is widely accepted and performed by most gynecologists. However, there isn't literature evidence to support the routine use of antibiotics in the prophylaxis of wound infection on laparoscopic pelvic surgery .Therefore, this study will evaluate the need for the use of antibiotic prophylaxis in gynecological laparoscopies not including opening hollow viscera. |
| NCT02078895 ↗ | Randomization of Botox for Stent Pain and Irritative Voiding Symptoms | Terminated | University of California, Irvine | Phase 3 | 2014-02-01 | Botulinum toxin type A (Botox A) has shown great success in treating certain urologic conditions. A recent study has documented that Botox injected around the ureteral orifice (or place where the tube that connects the kidney to the bladder enters the bladder), during placement of a ureteral stent (small rubber tube that facilitate drainage of urine from the kidney to the bladder), resulted in a marked decline in the amount of stent pain experienced by patients. This finding was quite remarkable as stents are commonly used in many Urologic conditions, and these stents produce a remarkable degree of patient discomfort. Despite the great improvement in pain reduction, the irritative voiding symptoms [frequent need to void, urgency, burning with urination (dysuria) or nighttime voiding (nocturia)] were not ameliorated by the Botox injections in the ureteral orifice. However, it has already been well documented that in other clinical settings, administrations of Botox into the bladder muscle, has been shown to reduce these irritative symptoms. The objective of the study is to determine if pain and irritative lower urinary tract symptoms related to ureteral stent placement will improve after the injection of Botox around the ureteral orifice and in the bladder itself. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for KEFZOL
Condition Name
Clinical Trial Locations for KEFZOL
Trials by Country
Clinical Trial Progress for KEFZOL
Clinical Trial Phase
Clinical Trial Sponsors for KEFZOL
Sponsor Name
